SOX4 suppresses vascular calcification via DNA-binding-independent regulation of the USP10-HNRNPC-WNT5A axis

Background: Vascular smooth muscle cell (VSMC) osteogenic differentiation drives vascular calcification, yet the endogenous mechanisms that restrain this transition remain poorly defined. SOX4 has recently emerged as a regulator of phenotype switching in endothelial and epithelial cells, but whether it governs VSMC fate and vascular calcification is unknown. Methods: SOX4 expression was examined in human calcified arteries, in vitamin D3 (VitD3)-treated mouse aortas and in phosphate-treated human aortic smooth muscle cells. Loss- and gain-of-function experiments, an HMG-box-deleted SOX4 mutant, co-immunoprecipitation combined with mass spectrometry, ubiquitination and protein stability assays, RNA immunoprecipitation sequencing and mRNA decay assays were combined with VSMC-specific Sox4 knockout mice and pharmacological WNT5A inhibition. Results: SOX4 protein was upregulated in calcified VSMCs and arteries, yet SOX4 loss aggravated and SOX4 overexpression attenuated VSMC osteogenic differentiation. A SOX4 mutant lacking the HMG-box retained anti-calcific activity, placing the function outside DNA binding. SOX4 interacted with HNRNPC and attenuated the HNRNPC-USP10 association, promoting K48-linked ubiquitination and proteasomal degradation of HNRNPC. HNRNPC bound WNT5A mRNA and was required for its stability, so that SOX4 reduced WNT5A expression. VSMC-specific Sox4 deletion aggravated VitD3-induced aortic calcification together with HNRNPC and WNT5A upregulation. Strengthening this braking axis with the WNT5A antagonist BOX5 attenuated VSMC osteogenic differentiation in vitro and vascular calcification in vivo in both genotypes, identifying WNT5A as a pharmacologically accessible node downstream of SOX4 loss. Conclusions: SOX4 restrains VSMC osteogenic differentiation through post-transcriptional control of cell fate, defining a SOX4-HNRNPC-WNT5A axis and identifying it as a pharmacologically accessible target for vascular calcification.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.16.767198
Primary Topic
Parathyroid Disorders and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

SOX4 suppresses vascular calcification via DNA-binding-independent regulation of the USP10-HNRNPC-WNT5A axis

Cong Qiu, Luyang Yu, 金晓宇, He Liu et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Parathyroid Disorders and Treatments
preprint

SOX4 suppresses vascular calcification via DNA-binding-independent regulation of the USP10-HNRNPC-WNT5A axis

Cong Qiu, Luyang Yu, 金晓宇, He Liu, He Cai, Junbo Chen, Yingyi Zhu, Kefan Ma, Xiaolong Zhu, Yi Li
preprint en

Abstract

Background: Vascular smooth muscle cell (VSMC) osteogenic differentiation drives vascular calcification, yet the endogenous mechanisms that restrain this transition remain poorly defined. SOX4 has recently emerged as a regulator of phenotype switching in endothelial and epithelial cells, but whether it governs VSMC fate and vascular calcification is unknown. Methods: SOX4 expression was examined in human calcified arteries, in vitamin D3 (VitD3)-treated mouse aortas and in phosphate-treated human aortic smooth muscle cells. Loss- and gain-of-function experiments, an HMG-box-deleted SOX4 mutant, co-immunoprecipitation combined with mass spectrometry, ubiquitination and protein stability assays, RNA immunoprecipitation sequencing and mRNA decay assays were combined with VSMC-specific Sox4 knockout mice and pharmacological WNT5A inhibition. Results: SOX4 protein was upregulated in calcified VSMCs and arteries, yet SOX4 loss aggravated and SOX4 overexpression attenuated VSMC osteogenic differentiation. A SOX4 mutant lacking the HMG-box retained anti-calcific activity, placing the function outside DNA binding. SOX4 interacted with HNRNPC and attenuated the HNRNPC-USP10 association, promoting K48-linked ubiquitination and proteasomal degradation of HNRNPC. HNRNPC bound WNT5A mRNA and was required for its stability, so that SOX4 reduced WNT5A expression. VSMC-specific Sox4 deletion aggravated VitD3-induced aortic calcification together with HNRNPC and WNT5A upregulation. Strengthening this braking axis with the WNT5A antagonist BOX5 attenuated VSMC osteogenic differentiation in vitro and vascular calcification in vivo in both genotypes, identifying WNT5A as a pharmacologically accessible node downstream of SOX4 loss. Conclusions: SOX4 restrains VSMC osteogenic differentiation through post-transcriptional control of cell fate, defining a SOX4-HNRNPC-WNT5A axis and identifying it as a pharmacologically accessible target for vascular calcification.

bioRxiv (Cold Spring Harbor Laboratory)
Sir Run Run Shaw Hospital (CN), Zhejiang University (CN)
Good health and well-being
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon